Zacks: Athenex Inc (ATNX) Given Consensus Recommendation of “Buy” by Analysts
Athenex Inc (NASDAQ:ATNX) has been given a consensus broker rating score of 2.00 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. Athenex’s rating score has declined by 33.3% from three months ago as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 1-year consensus target price of $25.73 for the company, according to Zacks. Zacks has also assigned Athenex an industry rank of 98 out of 265 based on the ratings given to its competitors.
Several equities research analysts have recently issued reports on ATNX shares. Credit Suisse Group started coverage on Athenex in a research report on Monday, September 18th. They issued an “outperform” rating and a $25.00 price target on the stock. Royal Bank Of Canada started coverage on Athenex in a research report on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price target on the stock. Laidlaw started coverage on Athenex in a research report on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price target on the stock. Finally, J P Morgan Chase & Co started coverage on Athenex in a research report on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price target on the stock.
Athenex (ATNX) opened at $16.62 on Tuesday. Athenex has a 1-year low of $11.21 and a 1-year high of $20.79.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc and related companies with MarketBeat.com's FREE daily email newsletter.